The U.S. Food and Drug Administration has approved INGREZZA Sprinkle (valbenazine) capsules, a new oral granules formulation of INGREZZA (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease, Neurocrine Biosciences Inc.

美国食品和药物管理局（FDA）批准了英格瑞扎（缬苯那嗪）胶囊，这是一种新的英格瑞扎（缬苯那嗪）胶囊口服颗粒制剂，用于治疗成人迟发性运动障碍和亨廷顿舞蹈病，Neurocrine Biosciences Inc。

(NBIX) said in a statement.INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.The U.S. Food and Drug Administration approval was based on chemistry, manufacturing, and controls information and data demonstrating the bioequivalence and tolerability of INGREZZA Sprinkle compared to INGREZZA capsules.For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News.

（NBIX）在一份声明中表示。INGREZZA Sprink为吞咽困难或吞咽困难的患者提供了另一种管理选择。美国食品和药物管理局的批准基于化学，制造和控制信息和数据，这些信息和数据证明了英格瑞扎喷雾剂与英格瑞扎胶囊相比的生物等效性和耐受性。有关更多此类健康新闻，请访问rttnews.com获取评论和反馈联系方式：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股